Oral lesions: A true clinical indicator in human immunodeficiency virus

Rajiv Saini

Department of Periodontology and Oral Implantology, Rural Dental College - Loni, Maharashtra, India

Address for correspondence:
Dr. Rajiv Saini, Department of Periodontology and Oral Implantology, Rural Dental College - Loni, Tehsil - Rahata, District - Ahmednagar, Maharashtra, - 413 736, India.
E-mail: drperiodontist@yahoo.co.in

Abstract

From the onset of the human immunodeficiency virus (HIV) epidemic over 20 years ago (since the appearance of the first cases of contamination by the HIV virus in the 1980s), more than 60 million people have become infected and more than 20 million people have died. An estimated 15,000 new infections occur each day, with more than 95% of these in developing countries. The distinctive characteristic in the pathogenesis of HIV/acquired immunodeficiency syndrome is that the primary target cell for HIV is immune cells bearing the CD4 marker at their surface, and the CD4 cell count and viral load have been used lately as the most important laboratory parameters to evaluate the evolution of the disease. Oral lesions are common (30–80%) in patients infected by the HIV virus and may indicate an impairment in the patient’s general health status and, consequently, a poor prognosis. Oral manifestations can suggest decreased cluster-differentiated (CD4+) T cell count and increased viral load, which might also aid in diagnosis, progression, and prognosis of the disease. At the tertiary level of oral care, a dentist should be available to make definitive diagnoses of oral lesions and provide professional oral services such as prophylaxis, restorations, biopsies, and the prescription of appropriate medication.

Key words: CD4, dental, HIV, oral

INTRODUCTION

HIV: Prevalence and epidemiology

Human immunodeficiency virus (HIV) causes progressive mutilation of the body's cellular immune system, leading to augmented susceptibility to tumors and fatal conditions such as acquired immunodeficiency syndrome (AIDS). The emergence and pandemic spread of AIDS constitute the greatest challenge to the public in modern times.[1] From the onset of the HIV epidemic over 20 years ago (since the appearance of the first cases of contamination by the HIV virus in the 1980s), more than 60 million people have become infected and more than 20 million people have died. More than 20 years into this HIV-AIDS pandemic, it has struck almost all the countries and populations in many ways. No disease has struck with such serious consequences as AIDS. It has devastating social, psychological, and financial ramifications. Currently, it is the fourth-leading cause of mortality worldwide.[3] AIDS, caused by HIV, is presently considered as one of the most dreadful diseases affecting human kind. An estimated 15,000 new infections occur each day, with more than 95% of these in developing countries. Sub-Saharan Africa currently bears the greatest burden worldwide, with 28.5 million (70%) individuals infected. In South Africa, 5.2 million of the population was estimated to be infected with HIV/AIDS. HIV is transmitted by sexual means, through the exchange of body fluids (especially infected semen during intercourse); by non-sexual means, via the parenteral transfer of infected blood; or through vertical transmission to infants born of infected mothers. The only fluids that have been demonstrated to be associated with transmission of the virus are blood, semen, breast milk, and vaginal secretions. Casual contact (shaking hands, hugging, casual kissing, etc.) has not been shown to transmit HIV. The United Nations Programme on HIV/AIDS estimates that over 40 million people are living with HIV/AIDS globally. An estimated 15,000 new infections occur each day, with more than...
95% of these in developing countries. Sub-Saharan Africa currently bears the greatest burden worldwide, with 28.5 million (70%) individuals infected. In South Africa, 5.2 million of the population was estimated to be infected with HIV/AIDS. Between 60% and 90% of the people with HIV infection will have at least one oral manifestation at some time during the course of their disease. Oral lesions cause significant discomfort and have a major impact on the quality of life. Recognition and management of these oral conditions is therefore important for the health and quality of life of the individual with HIV/AIDS. Despite the increasing number of reports on the prevalence of oral manifestations in HIV-positive/AIDS patients, there is limited information about the impact of these lesions on the quality of life in these patients.

Structure of human immunodeficiency virus
The HIVs are members of the retrovirus family of viruses. The retrovirus family is composed of three subfamilies: oncoviruses, spumaviruses and lentiviruses. Based on the structure, biologic properties, and protein and nucleic acid sequence homology, HIV is classified as lentivirus. A mature extracellular particle of HIV is characteristically 90–130 μm in diameter. HIV has a cylindrical eccentric nucleoid, or core. The nucleoid contains the HIV genome, which is diploid (i.e., composed of two identical single-stranded RNAs). Encoded in the RNA genome are the entire complements of genes of the virus. These genes code for the structural proteins that are used to assemble the virus particles and the regulatory proteins involved in the regulation of viral gene expression. The HIV RNA genome is associated with a basic nucleic acid-binding protein p9 and the reverse transcriptase (RT). The core or capsid antigen p24 encloses the nucleoid components, completing the nucleocapsid structure. The matrix antigen p17 encircles the viral core and lines the inner surface of the envelope of the virus. The surface of the HIV manifests external knob-like structures formed by the envelope glycoprotein gp120. The transmembrane protein (TMP) gp41 spans the viral membrane and has both external and internal domains. The TMP anchors the external gp 120 to the viral envelope. The membrane lipid bilayer is derived from the host cell plasma membrane.

Human immunodeficiency virus and immune system: CD4 target
The distinctive characteristic in the pathogenesis of HIV/AIDS is that the primary target cell for HIV is immune cells bearing the CD4 marker at their surface. With the infection of HIV, there will be gradual decrease of human immune cells bearing CD4 antigen receptor, the most important being T helper cells (CD4 T cells), B lymphocytes, macrophages, and natural killer cells. The CD4 cells coordinate a number of immunological functions, and as these cells are decrease the risk and severity of opportunistic infections (OI) increasing the death of the patients. It is stated that the absolute number of CD4 lymphocytes fall from a normal level of 800–900 μM to 60–100 per year. Because the loss of immune containment is associated with declining CD4 counts, the Centre for Disease Classification (CDC) stratifies patients with HIV infection into three categories on the basis of CD4 counts: CD4 counts ≥500 cells/mm³, 200–499 cells/mm³ and <200 cells/mm³. A CD4 count <200 cells/mm³ is associated with severe immune suppression, and the CDC in 1993 included all HIV-infected persons with such a count as fulfilling an AIDS-defining diagnosis. The amount of CD4 lymphocyte cells per milliliter and/or the quantity of RNA–HIV-1 copies per milliliter (viral load) are surrogate markers of HIV disease progression. It is known that HIV-positive patients with CD4 lymphocyte cells counts less than 200 per milliliter are severely immune depressed and HIV-positive patients with a viral load greater than 10,000 copies per milliliter show an active viremia. Although there have been reports of delayed antibody response to HIV1 infection, 95% or more of the infected persons develop detectable antibodies to HIV1 within 3–6 months. The interval between infection and seroconversion or detection of antibodies has been called the window period. The standard screening test for HIV infection is elaborated in Table 1.

Human immunodeficiency virus: Clinical presentation
Symptoms of HIV disease can appear at any time during the course of HIV infection. The spectrum of illness changes as the CD4+ T cell count declines. The more severe and life-threatening complications of HIV infection occur in patients with a CD4+ T cell count <200/μL. A diagnosis of AIDS is made in anyone with HIV infection and a CD4+ T cell count <200/μL and in anyone with HIV infection who develops one of the HIV-associated diseases considered to be indicative of a severe defect in cell-mediated immunity. While the causative agents of the secondary infections are characteristically opportunistic organisms such as P. carinii, atypical mycobacteria, cytomegalovirus (CMV), and other organisms that do not ordinarily cause disease in the absence of a compromised immune system, they also include common bacterial and mycobacterial pathogens. Approximately 60% of the deaths among AIDS patients are as a direct result of an infection other than HIV, with P. carinii, viral hepatitis, and non-AIDS defining bacterial infections heading the list. Following the widespread use of combination antiretroviral therapy and implementation of guidelines for the prevention of OIs, the incidence of secondary infections has decreased dramatically. Overall, the clinical spectrum of HIV disease is constantly changing.
as patients live longer and new and better approaches to treatment and prophylaxis are developed. In general, it should be stressed that a key element of the treatment of symptomatic complications of HIV disease, whether they are primary or secondary, is achieving good control of HIV replication through the use of combination antiretroviral therapy and instituting primary and secondary prophylaxis as indicated. Without treatment, HIV-infected patients will progress through the stages described in Table 2.

**Oral lesion in human immunodeficiency virus**

Oral lesions are common (30–80%) in patients infected by the HIV virus and may indicate an impairment in the patient’s general health status and, consequently, a poor prognosis. Many of these HIV-positive patients present manifestations involving the maxillofacial region in all stages of the disease, and, in some cases, the oral lesions are the first signs of infection. With disease progression, the deleterious effect of HIV on the immune system results in an escalating incidence of widely recognized and extensively described OIs and diseases, among which are the oral manifestations of HIV and, since the onset of the HIV pandemic, oral lesions have been well documented as early markers of HIV infection and as predictors of HIV disease progression. Oral manifestations can suggest decreased cluster-differentiated 4 (CD4+) T cell count and increased viral load, which might also aid in the diagnosis, progression, and prognosis of the disease. The risk of oral complication increases with immunologic deterioration. Oral examination is therefore useful for the early diagnosis, which can prolong the asymptomatic period, delay disease progression, and prevent OIs with proper education and

### Table 1: Standard screening test for HIV infection

| Laboratory detection test            | Scientific features                                                                 |
|--------------------------------------|-------------------------------------------------------------------------------------|
| ELISA (enzyme-linked immunoassay)    | Screening test                                                                      |
|                                      | Kit test (rapid results)                                                            |
|                                      | Not optimal with regard to specificity                                             |
|                                      | Confirmatory test to be followed upon                                              |
| Western blot                         | Most commonly used confirmatory test                                              |
|                                      | A Western blot demonstrating antibodies to products of all three of the major genes of HIV is conclusive evidence of HIV infection |
| p24 capture assay                    | Enzyme immunoassay                                                                  |
|                                      | Detects the viral protein p24 in the blood of HIV-infected individuals             |
|                                      | Screening test for HIV infection                                                   |
|                                      | p24 antigens are present prior to the development of antibodies                   |
| HIV RNA (in plasma)                  | Diagnostic tool in settings where measurements of anti-HIV antibodies may be misleading |
|                                      | In cases of acute infection and neonatal infection                                  |
|                                      | It includes reverse transcriptase PCR, branched DNA, and the nucleic acid sequence-based assay |

### Table 2: Stages of HIV progression

| Stages of HIV progression | Clinical manifestations                                                                 |
|---------------------------|----------------------------------------------------------------------------------------|
| Acute retroviral syndrome | 2–6 weeks following initial infection with HIV                                         |
|                           | Acute flu-like syndrome that may last 10–14 days                                       |
|                           | Syndrome of fever, generalized lymphadenopathy, pharyngitis, headache, myalgia, and arthralgia |
|                           | High levels of viral particles can be detected in the plasma                           |
|                           | CD4+ T cell count declines                                                             |
|                           | Seroconversion occurs                                                                 |
| Early chronic infection    | Lengthy phase (lasts for a decade or more)                                            |
|                           | CD4+ T cell counts will be normal or slightly decreased                                |
|                           | Viral loads will be low                                                                |
|                           | Asymptomatic phase, but can be associated with intermittent fatigue, headaches, night sweats, low-grade fevers, enlarged lymph nodes, weight loss, oral Candidiasis, malaise, and diarrhea |
| Intermediate chronic infection | Signals progression of HIV disease                                                   |
|                           | CD4+ T cell counts begin to decrease                                                  |
|                           | Viral load increases                                                                  |
|                           | Oral lesions                                                                         |
|                           | Chronic infection will become more persistent                                         |
| Late chronic infection (AIDS) | Appearance of symptoms of opportunistic diseases (viral, bacterial, fungal, or protozoal) |
|                           | Increased viral loads                                                                 |
|                           | Generalized lymphadenopathy, severe weight loss, fatigue, chronic diarrhea, chronic fever, and drenching night sweats |
|                           | CD4+ T cell count drops below 200 cells/mm³                                           |
|                           | Opportunistic cancers (Kaposi’s sarcoma, cervical carcinoma, Burkitts lymphoma, etc.) |
|                           | Dementia develops                                                                    |
|                           | Wasting syndrome occurs                                                               |
Table 3: Oral lesions associated with HIV

| Oral manifestation            | Clinical presentation                                                                                                                                 |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pseudomembranous candidosis  | Initial manifestation of symptomatic infection with HIV  
                                | Prevalence has been reported to be as high as 95%  
                                | Soft white/yellow, curd-like plaques on the oral mucosa  
                                | Deposits easily removable by gentle scraping |
| Erythematous candidosis      | Flat red patches on the dorsal surface of the tongue and hard palate  
                                | White spots and plaques may be seen, but these are not usually conspicuous |
| Angular cheilitis             | Red, ulcerated, and fissured lesion at the angle of the mouth |
| Hairy leukoplakia             | Asymptomatic bilateral, vertically corrugated, or hairy white lesions on the lateral borders of the tongue  
                                | Not removable  
                                | Lesions may rarely occur on the buccal mucosa |
| Linear gingival erythema      | Well-demarcated, linear band of intense redness along the gingival margins  
                                | Amount of erythema is disproportionately intense for the amount of plaque seen  
                                | No ulceration is present |
| Necrotising ulcerative gingivitis | Painful ulceration of the interdental papillae associated with halitosis and spontaneous gingival bleeding |
| Necrotising ulcerative periodontitis (NUP) | Rapidly progressive periodontal disease resulting in bone loss  
                                | Destruction or sequestration of bone may be seen, and the teeth may become loosened  
                                | Associated with severe pain (tooth sensitivity) |
| Necrotising ulcerative stomatitis | Extension of NUP into soft tissues  
                                | Bone sequestra |
| Kaposi’s sarcoma             | Painless purple/viioletaceous lesions on the palatal/anterior gingival mucosa; later becomes raised and ulcerated |
| Non-Hodgkin’s sarcoma        | Rapidly enlarging rubbery mass in the tonsillar fossa, palate, or gingival |
| Herpes simplex (HSV)         | Clusters of painful, small vesicles/ulcers on the palate or gingivae  
                                | Most cases of HSV infections are recurrent. Herpes labialis lesions are on the vermilion or mucoepithelial junction on the lips; form crusts on rupture  
                                | Herpes labialis is also known as cold sores |
| Herpes zoster                | Prodrome of pain, multiple vesicles on facial skin, lips, and intraoral structures. Follows the nerve distribution  
                                | May be complicated by post-herpetic neuralgia |
| Condyloma acuminata          | Warts are nodular or cauliflower-like in appearance, often multiple |
| Xerostomia                   | Dry mouth, often with fissured tongue. Promotes dental caries |
| Salivary gland swelling      | Unilateral/bilateral salivary gland swellings |
| Thrombocytopenic purpura      | Bleeding tendencies; petechiae on oral mucosa |
| Melanotic hyperpigmentation  | Melanotic linear lesions on the gingivae |
| Histoplasmosis               | Necrotic growth/ulcers |
| Cryptococcosis               | Necrotic ulcerative lesions |
| Tuberculous ulcers           | Ulcerative lesions usually on the tongue or gingivae  
                                | Usually patient has pulmonary TB |
| Lichenoid reactions          | White lace-like lesions on the oral mucosa |
| Erythema multiforme          | Ulcerative lip and intraoral lesions |
| Dental caries                | Dental decay |
| Trigeminal neuralgia         | Shock-like pain along the distribution of the trigeminal nerve |
| Facial palsy                 | Unilateral paresthaesia of the face |

Counseling of the patient. No particular oral lesion is uniquely associated with HIV infection. However, the presence of one or more lesions requires that HIV infection be considered as a possible underlying cause. Some oral lesions, such as oral candidiasis and oral hairy leukoplakia, are so strongly associated with HIV infection that they have been incorporated into the Centers for Disease Control and Prevention clinical classification of HIV disease. Oral manifestations frequently observed in HIV patients may be classified according to etiologic factors: fungal, viral, bacterial, and neoplastic infections. These lesions are often the first clinical symptoms of HIV infection and their diagnosis is an auxiliary method to raise early suspicion of AIDS. The various commonly associated oral lesions with HIV are illustrated in Table 3. Clinical stages of oral lesions associated with HIV with respect to its occurrence are illustrated in Table 4.

Effect of antiretroviral therapy on oral lesions
In the recent years, the management of HIV-positive
individuals has been based on highly active antiretroviral therapy (HAART), comprising a combination of nucleoside analogue RT inhibitors and at least one protease inhibitor and/or one non-nucleoside analogue RT inhibitor. HAART induces a marked reduction of viral replication and increases the CD4+ cell count. Since the introduction of HAART in the mid-1990s, it has been accompanied by a reduction in the frequency of many of the secondary events caused by HIV infection, including some oral lesions.[17] Since the advent of HAART, studies had shown a decline in the prevalence of oral lesions associated with HIV/AIDS. These lesions include: oral candidiasis, hairy leukoplakia, Kaposi’s sarcoma, herpes simplex labialis, and periodontal disease.[18]

**CONCLUSION**

The World Health Organization (WHO) Global Oral Health Program recently formulated policies for the prevention of oral manifestations in HIV/AIDS.[19] Prevention of HIV/AIDS-related oral disease is based on the involvement of primary healthcare workers as well as oral health professionals in the early detection and screening, on the integration of oral disease prevention and oral health promotion into community and national HIV/AIDS programmes, and on the WHO technical support to build capacity in countries. By using a systematic approach and giving the patient a complete oral examination, the dentist can be able to diagnose oral lesions in patients with HIV disease. Rather than trying to guess the correct diagnosis, a good diagnostician should obtain the history of the lesion, should evaluate signs and symptoms, and should determine the possible etiology. Important factors to be considered in the differential diagnosis are the history of the lesions, the clinical appearance, location, and symptoms like pain, burning sensation, and discomfort upon deglutition. It is also important to consider the nature of the lesion. An oral mucosal lesion can be reactive, inflammatory, infectious, or malignant. It can be a localized process or part of a systemic disease. From the analysis of the data collected during clinical examination, the dentist can construct a list of differential diagnoses, listing the most probable disease that could cause that particular lesion. This procedure should lead to the final diagnosis of the disease and indicate the most appropriate treatment. Not uncommonly, oral lesions in HIV patients can cause severe impairment of oral functions as well as pain and discomfort and, in addition, they are a manifestation of opportunistic diseases secondary to systemic immunosuppressant. Therefore, from the oral cavity, they may disseminate systemically and cause a much more dangerous threat to the patient’s health. Some of the lesions may be transmissible and patients must be counseled on the prevention of transmission (e.g., Herpes, syphilis, tuberculosis). HIV-related oral abnormalities are present in 30–80% of the HIV-infected individuals, and these abnormalities are often inaccurately described in medical care. Dental expertise is necessary for the proper management of oral complications in HIV infection or AIDS. Medical clinicians should be able to recognize HIV-associated oral disease and to provide appropriate care and referral. At the tertiary level of oral care, a dentist should be available to make definitive diagnoses of oral lesions and provide professional oral services such as prophylaxis, restorations, biopsies, and the prescription of appropriate medication. There is a need for dentists to be involved throughout the management of HIV patients and not only at the tertiary level of care. There is also a need for training and retraining of medical personnel in the diagnosis and management of HIV-associated oral lesions and appropriate patient referral.

**REFERENCES**

1. Ananthanarayan R, Panicker J. Text book of microbiology. 5th ed. Madras: Orient Longman Publishers; 1996. p. 538-52.
2. Fauci AS, Lane HC. Human Immunodeficiency Virus Disease: AIDS and Related Disorders. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, editors. Harrison’s Principles of Internal Medicine, Vol. 1. 16th ed. New York: McGraw-Hill; 2005. p. 1076-139.
3. Schochetman G. Biology of Human Immunodeficiency Viruses. In: George JR, Ward JW, editors. AIDS Testing, 2nd ed. New York: Springer Verlag Publishers; 1994. p. 15-51.
4. Chan RK. Early clinical manifestation of HIV infection. Singapore Med J 1990;31:477-9.
5. Beverly P, Helbert M. Immunology of AIDS; ABC of AIDS, 4th ed. New York: BMJ Publication Group; 1997. p. 11-2.
6. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kinsley L. Prognosis of HIV-1 contagious predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
7. Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB, et al. Prognostic indicators for AIDS and contagious disease death in HIV-infected drug users: Plasma viral load and CD4+ cell count. JAMA 1998;279:35-40.
8. Mellors JW, Muñoz A, Girodi JV. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
9. Faria PR, Vargas PA, Saldiva PH, Bohm GM, Mauad T, Almeida OP.
Saini: Oral profile in human immunodeficiency virus

Tongue disease in advanced AIDS. Oral Dis 2005;11:72-80.
10. Nittayananta W, Chungpanich S. Oral lesions in a group of Thai people with AIDS. Oral Dis 1997;3:541-5.
11. Greenspan D, Greenspan JS. Oral mucosal manifestations of AIDS. Dermatol Clin 1987;5:733-7.
12. Patton LL, Phelan JA, Ramos-Gomez FJ, Nittayananta W, Shiboski CH, Mbuguye TL. Prevalence and classification of HIV-associated oral lesions. Oral Dis 2002;8:98-109.
13. Margiotta V, Campisi G, Mancuso S, Accurso V, Abbadesa V. HIV infection: Oral lesions, CD4+ cell count and viral load in an Italian study population. J Med 1999;28:173-7.
14. Birnbaum W, Hodgson TA, Reichart PA, Sherson W, Nittayannanta SW, Axell TE. Prognostic significance of HIV-associated oral lesions and their relation to therapy. Oral Dis 2002;8:110-4.
15. Greenspan JS, Greenspan D. The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis 2002;8:34-9.
16. Leggot PJ. Oral manifestations of HIV infection in children. Oral Surg Oral Med Oral Pathol 1992;73:187-93.
17. Schmidt-Westhausen AM, Priepe F, Bergman FJ, Reichart PA. Decline in the rate of oral opportunistic infections following introduction of highly active retroviral therapy. J Oral Pathol Med 2000;29:336-41.
18. Bendick C, Schelfele C, Reichart PA. Oral manifestations in 101 Cambodian patients with HIV infection and AIDS. J Oral Pathol Med 2002;31:1-4.
19. Petersen PE. Policy for prevention of oral manifestations in HIV/AIDS: The approach of the WHO Global Oral Health Program. Adv Dent Res 2006;19:17-20.

How to cite this article: Saini R. Oral lesions: A true clinical indicator in human immunodeficiency virus. J Nat Sc Biol Med 2011;2:145-50.

Source of Support: Nil. Conflict of Interest: None declared.

Staying in touch with the journal

1) Table of Contents (TOC) email alert
   Receive an email alert containing the TOC when a new complete issue of the journal is made available online. To register for TOC alerts go to www.jnsbm.org/signup.asp.

2) RSS feeds
   Really Simple Syndication (RSS) helps you to get alerts on new publication right on your desktop without going to the journal’s website. You need a software (e.g. RSSReader, Feed Demon, FeedReader, My Yahoo!, NewsGator and NewsCrawler) to get advantage of this tool. RSS feeds can also be read through FireFox or Microsoft Outlook 2007. Once any of these small (and mostly free) software is installed, add www.jnsbm.org/rssfeed.asp as one of the feeds.